Kondoros Balázs Attila, Jójárt-Laczkovich Orsolya, Berkesi Ottó, Szabó-Révész Piroska, Csóka Ildikó, Ambrus Rita, Aigner Zoltán
Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, H-6720 Szeged, Hungary.
Department of Physical Chemistry and Materials Science, Faculty of Science and Informatics, University of Szeged, H-6720 Szeged, Hungary.
Pharmaceutics. 2022 Mar 30;14(4):744. doi: 10.3390/pharmaceutics14040744.
Molecular complexation with cyclodextrins (CDs) has long been a known process for modifying the physicochemical properties of problematic active pharmaceutical ingredients with poor water solubility. In current times, the focus has been on the solvent-free co-grinding process, which is an industrially feasible process qualifying as a green technology. In this study, terbinafine hydrochloride (TER), a low solubility antifungal drug was used as a model drug. This study aimed to prepare co-ground products and follow through the preparation process of the co-grinding method in the case of TER and two amorphous CD derivatives: (2-hydroxypropyl)-β-cyclodextrin (HPBCD); heptakis-(2,6-di-O-methyl)-β-cyclodextrin (DIMEB). For this evaluation, the following analytical tools and methods were used: phase solubility studies, differential scanning calorimetry (DSC), X-ray powder diffractometry (XRPD), hot-stage X-ray powder diffractometry (HOT-XRPD), Fourier-transform infrared (FT-IR), Raman spectroscopy, and Scanning Electron Microscopy (SEM). Furthermore, in vitro characterization (dissolution and diffusion studies) was performed in two kinds of dissolution medium without enzymes. In the XRPD and SEM studies, it was found that the co-grinding of the components resulted in amorphous products. FT-IR and Raman spectroscopies confirmed the formation of an inclusion complex through the unsaturated aliphatic chain of TER and CDs. In vitro characterization suggested better dissolution properties for both CDs and decreased diffusion at higher pH levels in the case of HPBCD.
长期以来,与环糊精(CDs)形成分子络合物一直是改善难溶性活性药物成分物理化学性质的已知方法。目前,重点在于无溶剂共研磨工艺,这是一种符合绿色技术标准且在工业上可行的工艺。在本研究中,低溶解度抗真菌药物盐酸特比萘芬(TER)被用作模型药物。本研究旨在制备共研磨产物,并在TER与两种无定形CD衍生物的情况下,遵循共研磨法的制备过程:(2-羟丙基)-β-环糊精(HPBCD);七(2,6-二-O-甲基)-β-环糊精(DIMEB)。为进行此评估,使用了以下分析工具和方法:相溶解度研究、差示扫描量热法(DSC)、X射线粉末衍射法(XRPD)、热台X射线粉末衍射法(HOT-XRPD)、傅里叶变换红外光谱(FT-IR)、拉曼光谱和扫描电子显微镜(SEM)。此外,在两种无酶溶解介质中进行了体外表征(溶解和扩散研究)。在XRPD和SEM研究中,发现各组分的共研磨产生了无定形产物。FT-IR和拉曼光谱通过TER的不饱和脂肪链和CDs证实了包合物的形成。体外表征表明,两种CDs均具有更好的溶解性能,并且在HPBCD的情况下,在较高pH值下扩散降低。